Melanoma, BRAF V600 Mutation, Cobas®
Test Code
Clinical Significance
Melanoma, BRAF V600 Mutation, Cobas® - This FDA-cleared real-time PCR assay on the cobas 4800 platform assesses for mutations at codon 600 of BRAF, particularly V600E, which are present in 40-60% of melanomas. Melanomas with codon 600 BRAF mutations are associated with response to the BRAF-directed kinase inhibitor vemurafenib (ZELBORAF®).
Tumor DNA is extracted from fixed tumor tissue and subjected to real-time PCR, with approximate sensitivity of 5% mutation-bearing cells in a mixed sample. Other codon 600 BRAF mutations, beside the most common V600E (c.1799T>A) may not be detected by this method.
Test Resources
Test Details
Methodology
Reference Range(s)
Alternative Name(s)
Preferred Specimen(s)
Formalin-fixed paraffin embedded tissue
Alternative Specimen(s)
Slides accepted only after contacting Oncology Center as listed in instructions
Collection Instructions
Slides: Please contact the Oncology Center at 1(800)642-4657 x2906, prior to submission of slides for detailed instructions.
Freezing is not recommended for FFPE.
Transport Container
Formalin-fixed paraffin embedded tissue block
Transport Temperature
Room temperature
Specimen Stability
- Room temperature: Indefinite
- Refrigerated: Indefinite
- Frozen: Unacceptable
Reject Criteria
Received frozen
Setup Schedule
Freezing is not recommended for FFPE.
Refrigerated: Indefinite
Frozen: Unacceptable